Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0268596 (
EMA
)
2,520
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The high complexity of n-3 fatty acids absorption process, along with the huge amount of endogenous fraction, makes bioavailability studies with these agents very challenging and deserving special consideration. In this paper we report the results of a bioequivalence study between a new formulation of EPA+DHA ethyl esters developed by IBSA Institut Biochimique and reference medicinal product present on the Italian market. Bioequivalence was demonstrated according to the criteria established by the
EMA
Guideline on the Investigation of Bioequivalence. We found that the free fractions represent a better and more sensitive end-point for bioequivalence investigations on n-3 fatty acids, since: (i) the overall and intra-subject variability of PK parameters was markedly lower compared to the same variability calculated on the total
DHA
and EPA fractions; (ii) the absorption process was completed within 4h, and the whole PK profile could be drawn within 12-15 h from drug administration.
...
PMID:The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids. 2555 40
Omega-3 long-chain polyunsaturated fatty acid (
n
-3 FA) status may be associated with mood disorders. Here, we evaluated the potential association between antenatal depression/anxiety and
n
-3/
n
-6 FA in (a) maternal erythrocytes and (b) human milk. In addition, we explored associations between
n
-3/
n
-6 FA in erythrocytes and in human milk and postpartum depression, while controlling for antenatal depression. Twenty-seven pregnant women diagnosed with a current major depressive disorder (MDD;
n
= 9), anxiety disorder (AD;
n
= 10) or a mixed anxiety-depression disorder (
MADD
;
n
= 8), and 40 healthy controls were included.
n
-3/
n
-6 FA were determined in maternal erythrocytes in gestational week 32 and in human milk in postpartum week 1. In the first week postpartum, the
Edinburgh
-
Postnatal
-
Depression
-
Questionnaire
was used to assess postpartum depression. Results show that women with M(A)DD had significantly lower erythrocyte levels of total
n
-3 FA, EPA,
DHA
and DGLA, and significantly higher
n
-6 DPA, and
n
-6:
n
-3, AA:EPA and
n
-6 DPA:
DHA
ratios compared to healthy controls. No significant associations between antenatal depression or anxiety and
n
-3/
n
-6 FA in human milk were found. After controlling for antenatal mental health,
n
-3/
n
-6 FA in maternal erythrocytes or in human milk were not significantly associated with postpartum depression. In conclusion, antenatal depression, alone or with an anxiety disorder, was associated with lower
n
-3 FA levels and higher
n
-6:
n
-3 FA ratios in maternal erythrocytes during gestation. This study provides some insights into the associations between
n
-3/
n
-6 FA levels during pregnancy and lactation and perinatal mental health.
...
PMID:Levels of
n
-3 and
n
-6 Fatty Acids in Maternal Erythrocytes during Pregnancy and in Human Milk and Its Association with Perinatal Mental Health. 3293 15